A Secret Weapon For LY 3000328
All enrolled individuals who gained no less than 1 dose of zosuquidar or placebo throughout induction have been monitored for that prevalence of adverse occasions (439 sufferers, 219 on zosuquidar and 210 on placebo). The most typical adverse situations were associated with the period of prolonged and considerable myelosuppression as is predicted w